“ADME” or “Toxicokinetics” is the process of studying the body’s absorption, distribution, metabolism, and excretion of foreign chemicals.
Medicilon Drug Safety Evaluation Service>>
The toxicokinetics study used repeated doses of the toxicity test dose to study the dynamic changes of drugs in vivo, and obtained pharmacokinetic data. It is usually carried out in conjunction with repeated administration of toxicity tests. If appropriate parameters are determined, repeated tests can be avoided. Toxicokinetics is an integral part of the design of non-clinical trials. In understanding the results of toxicity studies and comparing them with clinical data to evaluate safety for humans, the focus is on interpreting the results of toxicity tests and increasing the value of safety assessment data. The purpose of the toxicokinetics study is to know the degree and duration of systemic exposure of the test substance at different dose levels in the toxicity test, and to predict the potential risk of the test substance in human exposure.
At present, the Medicilon Toxicokinetics Test Center has carried out comprehensive reproductive toxicity tests (paragraphs I, II, III), genotoxicity tests (Ames, micronucleus, chromosome aberrations), local toxicity tests, immunogenicity tests, Studies on safety pharmacology, toxicokinetics, carcinogenesis, etc.
The main values of toxicokinetics research in safety evaluation are:
(1) Describe the systemic exposure of the test substance and/or its metabolites in the toxicity test and its dose and time relationship with the toxic reaction; evaluate the test substance and/or its metabolite in different animal species, sex, age, Toxicity of body status (eg pregnancy status); Evaluate the rationality of animal species selection and medication regimen for non-clinical toxicity studies.
(2) Improve the predictive value of animal toxicity test results for clinical safety evaluation. Evaluating the target site toxicity (such as liver or kidney toxicity) caused by the accumulation of the test substance based on the exposure amount helps to provide quantitative safety information for the subsequent safety evaluation.
(3) Comprehensive drug efficacy and exposure and toxicity and exposure information to guide the design of human trials, such as initial dose, safety range evaluation, etc., and guide clinical safety monitoring according to the degree of exposure.
Plasma protein binding
Tissue uptake
Receptor properties
Species differences in metabolic characteristics
Pharmacological activity of metabolites
Immunogenicity and toxicology
| Test type | Animal species | Drug type | Route of administration | research content |
| Pharmacy / Poison | Mice Rat Guinea pig Rabbit Beagles | Small molecule Biological Natural products Vaccine Traditional Chinese medicine | Oral: gavage, capsule Parenteral: intraperitoneal injection, intravenous injection, intramuscular injection, intradermal injection, subcutaneous injection, continuous infusion, intravitreal injection Others: nasal feeding, nasal cavity, eyes, rectum, vagina, implantation | Drug absorption, distribution, metabolism and excretion PK/TK Bioequivalence Bioavailability (po, sc, im, ip, etc.) Organizational distribution PK/PD study of a rodent disease model for dose design and dosing regimen PK research on the development and evaluation of pharmaceutical preparations Special PK studies, including food effects, gender factors, drug interactions, and the effect of gastric pH on drug PK Plasma protein binding (equilibrium dialysis and ultrafiltration) |
Our Staff
Design the dosing regimen of the toxicokinetic test
Collect samples in time according to the frequency required for exposure assessment
Analysis of analyte and biological matrix (biological fluid or tissue)
Data statistics and evaluation
Write an experimental report based on complete toxicokinetic data
contact us
Email: marketing@medicilon.com
Phone: 021 58591500
Medicilon Drug Metabolite Analysis Service
Medicilon Metabolomics Technical Services
Pharmacokinetic Research Services
Relevant
news
marketing@medicilon.com
